Jacobs Levy Equity Management Inc. Has $2.32 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Jacobs Levy Equity Management Inc. boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 660.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 34,609 shares of the medical device company's stock after purchasing an additional 30,058 shares during the period. Jacobs Levy Equity Management Inc.'s holdings in DexCom were worth $2,320,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Ascent Group LLC lifted its position in shares of DexCom by 7.9% during the 3rd quarter. Ascent Group LLC now owns 7,950 shares of the medical device company's stock worth $533,000 after buying an additional 583 shares during the last quarter. Benjamin Edwards Inc. acquired a new position in DexCom during the third quarter worth about $652,000. Erste Asset Management GmbH acquired a new position in DexCom during the third quarter worth about $694,000. Caisse DE Depot ET Placement DU Quebec lifted its holdings in shares of DexCom by 235.0% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 135,323 shares of the medical device company's stock worth $9,072,000 after acquiring an additional 94,923 shares during the last quarter. Finally, PDT Partners LLC boosted its stake in shares of DexCom by 164.3% in the 3rd quarter. PDT Partners LLC now owns 52,290 shares of the medical device company's stock valued at $3,506,000 after purchasing an additional 32,508 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on DXCM shares. Sanford C. Bernstein upped their price objective on shares of DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a research report on Friday, October 25th. Oppenheimer lowered their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Wells Fargo & Company raised their price objective on DexCom from $80.00 to $90.00 and gave the company an "overweight" rating in a report on Friday, October 25th. Stifel Nicolaus boosted their price objective on DexCom from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, August 23rd. Finally, Royal Bank of Canada dropped their target price on DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a research report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $104.59.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company's stock, valued at approximately $18,318,872.25. The trade was a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of the company's stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. This represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,431 shares of company stock valued at $399,319 in the last ninety days. 0.30% of the stock is owned by company insiders.

DexCom Trading Down 1.5 %

DXCM stock traded down $1.20 during midday trading on Friday, hitting $77.72. The stock had a trading volume of 2,644,207 shares, compared to its average volume of 3,793,395. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The business has a fifty day moving average price of $72.55 and a two-hundred day moving average price of $85.74. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The firm has a market cap of $30.36 billion, a P/E ratio of 46.54, a price-to-earnings-growth ratio of 2.48 and a beta of 1.12.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.